Coherus Oncology CHRS
NASDAQ CHRS
$0.75 +0.00 (+0.56%)
As of: Nov 6, 2026 · 9:54 AM EST

Coherus Oncology (CHRS) Long-Term Debt Repayments (2022)

Updated

Coherus Oncology (CHRS) posted Long-Term Debt Repayments of $233.19 million for FY2025, down 10.4% from $260.39 million in FY2024.

Analysis

Coherus Oncology (CHRS) Long-Term Debt Repayments (2022) Analysis & Trends

Since FY2020, Coherus Oncology has reported Long-Term Debt Repayments for 5 years.

  • Annual Long-Term Debt Repayments shows a five-year compound annual growth rate of 259.4% (FY2020 to FY2025).
  • The FY2025 figure stands as the lowest annual Long-Term Debt Repayments since FY2022.
  • Business Quant data shows CHRS's Long-Term Debt Repayments at $260.39 million in FY2024, $109 million in FY2022 and $672,000 in FY2021 (+72.8%).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) LT Debt Repayment (Qtr)
1 Eli Lilly 1,221.54 Bn 1,195.15 Bn 20.46 Bn -
2 Johnson & Johnson 650.21 Bn 570.07 Bn 17.30 Bn 1.00 Mn
3 AbbVie 508.24 Bn 476.24 Bn 13.12 Bn -
4 Merck 360.07 Bn 323.01 Bn 13.19 Bn -
5 Novartis Ag 312.26 Bn 285.49 Bn - -
6 Astrazeneca 285.31 Bn 259.20 Bn 13.26 Bn -4.91 Bn
7 Amgen 247.74 Bn 199.39 Bn 7.58 Bn 3.05 Bn
8 Gilead Sciences 207.12 Bn 182.22 Bn 6.73 Bn 19.00 Mn
9 Pfizer 166.13 Bn 113.48 Bn 12.56 Bn -
10 Coherus Oncology 116.17 Mn -519.97 Mn 10.07 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2022 -81.75 Mn
Mar 31, 2022 190.75 Mn
API Access

Coherus Oncology Long-Term Debt Repayments API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=long-term-debt-repayments&ticker=CHRS&period=max&api_key=YOUR_API_KEY